HC Wainwright Increases Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $92.00
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its target price raised by analysts at HC Wainwright from $82.00 to $92.00 in a report issued on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 44.02% from the company’s previous close. […]
More Stories
What is Cormark’s Estimate for FPX Nickel FY2026 Earnings?
FPX Nickel Corp. (CVE:FPX – Free Report) – Stock analysts at Cormark issued their FY2026 EPS estimates for FPX Nickel...
Roth Capital Cuts Earnings Estimates for ReNew Energy Global
ReNew Energy Global PLC (NASDAQ:RNW – Free Report) – Investment analysts at Roth Capital dropped their Q1 2026 earnings per...
FY2026 EPS Estimates for MannKind Cut by Leerink Partnrs
MannKind Corporation (NASDAQ:MNKD – Free Report) – Investment analysts at Leerink Partnrs decreased their FY2026 earnings per share estimates for...
FY2026 EPS Estimate for AST SpaceMobile Decreased by Analyst
AST SpaceMobile, Inc. (NASDAQ:ASTS – Free Report) – Analysts at B. Riley dropped their FY2026 EPS estimates for shares of...
Equities Analysts Offer Predictions for CGBD Q1 Earnings
Carlyle Secured Lending, Inc. (NASDAQ:CGBD – Free Report) – Stock analysts at B. Riley issued their Q1 2026 earnings per...
What is B. Riley’s Forecast for MAIN Q1 Earnings?
Main Street Capital Corporation (NYSE:MAIN – Free Report) – Equities research analysts at B. Riley issued their Q1 2026 earnings...